SequelSEC

Alto Neuroscience, Inc. ANRO

Pharmaceutical Preparations · CIK 0001999480 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$66.36M
Fiscal year ended 2025-12-31
Free cash flow
-$51.79M
Fiscal year ended 2025-12-31

Alto Neuroscience, Inc. (ANRO) reported net income of -$63.24M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Alto Neuroscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Alto Neuroscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$66.36M-$68.61M-$37.81M
Net income-$63.24M-$61.43M-$36.30M
Research & development$45.62M$47.00M$30.29M
Weighted-average diluted sharesshares 28.85Mshares 24.60Mshares 3.73M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expense$0$0$0
Diluted EPS$-2.19$-2.50$-9.73
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$20.74M$21.61M$7.52M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Alto Neuroscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$176.48M$168.23M$82.55M
Total assets$184.69M$177.54M$86.63M
Current assets$177.72M$169.34M$85.39M
Total liabilities$33.55M$26.08M$16.82M
Current liabilities$11.32M$10.01M$5.61M
Total equity incl. NCI$151.14M$151.46M-$71.67M
Temporary (mezzanine) equity$0$0$141.48M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debt$16.17M$10.25M$9.86M
Accounts payable$1.88M$1.58M$1.07M

Cash flow

Alto Neuroscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$51.77M-$47.42M-$33.45M
Capital expenditures$24.00K$2.08M$470.00K
Investing cash flow-$24.00K-$2.08M-$470.00K
Financing cash flow$60.08M$135.69M$68.13M
Net change in cash$8.26M$86.18M$34.20M
Stock-based compensation$8.11M$7.63M$2.89M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$502.00K$373.00K

Derived

Alto Neuroscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$51.79M-$49.50M-$33.92M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio15.69x16.92x15.22x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equity0.11xUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ANRO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.